BR112021016522A2 - Composição farmacêutica para o tratamento da leucemia mieloide aguda - Google Patents
Composição farmacêutica para o tratamento da leucemia mieloide aguda Download PDFInfo
- Publication number
- BR112021016522A2 BR112021016522A2 BR112021016522-3A BR112021016522A BR112021016522A2 BR 112021016522 A2 BR112021016522 A2 BR 112021016522A2 BR 112021016522 A BR112021016522 A BR 112021016522A BR 112021016522 A2 BR112021016522 A2 BR 112021016522A2
- Authority
- BR
- Brazil
- Prior art keywords
- methyl
- indol
- pyrimidin
- chloro
- flt3
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2019-0021228 | 2019-02-22 | ||
| KR20190021228 | 2019-02-22 | ||
| PCT/KR2020/002536 WO2020171646A1 (ko) | 2019-02-22 | 2020-02-21 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
| KR1020200021502A KR20200102949A (ko) | 2019-02-22 | 2020-02-21 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
| KR10-2020-0021502 | 2020-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021016522A2 true BR112021016522A2 (pt) | 2021-10-26 |
Family
ID=72144358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021016522-3A BR112021016522A2 (pt) | 2019-02-22 | 2020-02-21 | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12433867B2 (https=) |
| JP (1) | JP7577672B2 (https=) |
| BR (1) | BR112021016522A2 (https=) |
| CL (1) | CL2021002217A1 (https=) |
| MX (1) | MX2021010115A (https=) |
| PE (1) | PE20212153A1 (https=) |
| PH (1) | PH12021551985A1 (https=) |
| WO (1) | WO2020171646A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| EA202290154A1 (ru) | 2019-06-27 | 2022-03-29 | Ханми Фарм. Ко., Лтд. | Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| KR20230056331A (ko) * | 2021-10-20 | 2023-04-27 | 한미약품 주식회사 | 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합 |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| WO2023225005A1 (en) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| AU2007325280B2 (en) | 2006-11-28 | 2011-03-10 | Dana-Farber Cancer Institute, Inc. | Combination of IAP inhibitors and FLT3 inhibitors |
| EP2133095A4 (en) | 2007-03-05 | 2012-09-26 | Kyowa Hakko Kirin Co Ltd | PHARMACEUTICAL COMPOSITION |
| JP2011500808A (ja) | 2007-10-24 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環アミドｔ型カルシウムチャネルアンタゴニスト |
| FR2926553B1 (fr) | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
| US20110183975A1 (en) | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| UY32203A (es) | 2008-10-29 | 2010-05-31 | Astrazeneca Ab | Amino pirimidinas y su uso en terapia |
| CA2755976C (en) | 2009-03-23 | 2020-04-07 | Ambit Biosciences Corporation | Methods of treatment using combination therapy |
| CN102471339A (zh) | 2009-07-15 | 2012-05-23 | 雅培制药有限公司 | 激酶的吡咯并吡啶抑制剂 |
| MX342164B (es) | 2010-06-23 | 2016-09-19 | Hanmi Science Co Ltd | Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa. |
| UY33539A (es) | 2010-08-02 | 2012-02-29 | Astrazeneca Ab | Compuestos químicos alk |
| EP4119551A1 (en) | 2011-07-27 | 2023-01-18 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
| WO2013146963A1 (ja) | 2012-03-28 | 2013-10-03 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2014155300A2 (en) | 2013-03-28 | 2014-10-02 | Aurigene Discovery Technologies Limited | Substitued pyrimidine amine derivatives as tak-1 inhibitors |
| CN110229142A (zh) | 2014-04-04 | 2019-09-13 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| EP3778584A1 (en) | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives |
| CN106458969A (zh) | 2014-08-25 | 2017-02-22 | 四川海思科制药有限公司 | 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 |
| CN105085489B (zh) | 2014-11-05 | 2019-03-01 | 益方生物科技（上海）有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| CA2976752C (en) | 2015-02-20 | 2019-12-17 | Daiichi Sankyo Company, Limited | Method for treating cancer by combined use |
| WO2016155655A1 (zh) | 2015-04-03 | 2016-10-06 | 上海瑛派药业有限公司 | Parp抑制剂固体药物剂型及其应用 |
| KR101799781B1 (ko) | 2015-07-23 | 2017-11-22 | 재단법인 강릉과학산업진흥원 | 소뼈 추출분말의 제조방법 |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| KR102110573B1 (ko) | 2015-08-13 | 2020-05-13 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
| AU2016324920B2 (en) | 2015-09-14 | 2022-03-03 | Brunangelo Falini | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia |
| US10927418B2 (en) | 2015-11-11 | 2021-02-23 | Celator Pharmaceuticals, Inc. | Assays and methods for selecting a treatment regimen for a subject with leukemia |
| CA3017408C (en) | 2016-03-15 | 2025-08-19 | Oryzon Genomics, S.A. | LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS |
| CA3018155A1 (en) * | 2016-03-29 | 2017-10-05 | Astellas Pharma Inc. | Combination therapy for the treatment of acute myeloid leukemia |
| ES2805976T3 (es) | 2016-06-30 | 2021-02-16 | Janssen Pharmaceutica Nv | Derivados heteroaromáticos en calidad de inhibidores de NIK |
| WO2018092020A1 (en) | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
| US20200039998A1 (en) | 2016-12-19 | 2020-02-06 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
| ES2938648T3 (es) | 2017-01-17 | 2023-04-13 | Astrazeneca Ab | Inhibidores selectivos de JAK1 |
| KR102175710B1 (ko) | 2017-01-23 | 2020-11-06 | 주식회사 엘지화학 | 폴리아릴렌 설파이드 수지 조성물 |
| EP3789386A1 (en) | 2017-01-26 | 2021-03-10 | Hanmi Pharm. Co., Ltd. | Pyrimidine compound and pharmaceutical use thereof |
| TWI821174B (zh) | 2017-02-21 | 2023-11-11 | 加拿大商艾普托斯生物科學公司 | 治療血液惡性腫瘤患者的方法 |
| EP3661511A1 (en) | 2017-08-01 | 2020-06-10 | Julius-Maximilians-Universität Würzburg | Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia |
| AU2018354423B2 (en) | 2017-10-27 | 2024-11-07 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| EP3755703B1 (en) | 2018-02-20 | 2022-05-04 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR102297587B1 (ko) | 2018-08-07 | 2021-09-06 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| CN113166110B (zh) | 2018-12-12 | 2023-08-11 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| WO2020171649A1 (ko) | 2019-02-22 | 2020-08-27 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| KR20200102949A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
| EA202290154A1 (ru) | 2019-06-27 | 2022-03-29 | Ханми Фарм. Ко., Лтд. | Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты |
| KR20210038366A (ko) | 2019-09-30 | 2021-04-07 | 한미약품 주식회사 | Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| CN115151534B (zh) | 2020-02-14 | 2024-02-06 | 南京药石科技股份有限公司 | 白细胞介素-1受体相关激酶(irak)/fms样受体酪氨酸激酶(flt3)的抑制剂、其药物产品及其方法 |
| EP4241773A4 (en) | 2020-11-05 | 2024-10-16 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEUKEMIA WITH FLT3 INHIBITOR |
| KR20230056331A (ko) | 2021-10-20 | 2023-04-27 | 한미약품 주식회사 | 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합 |
| AU2023372170A1 (en) | 2022-11-04 | 2025-04-24 | Hanmi Pharm. Co., Ltd. | Novel crystalline form of a pyrimidine compound and pharmaceutical compositions comprising the same and methods of use thereof |
| WO2024124199A1 (en) | 2022-12-10 | 2024-06-13 | Aptose Biosciences Inc. | Methods for treating patients with hematologic malignancies |
| CN121586574A (zh) | 2023-05-31 | 2026-02-27 | 韩美药品株式会社 | 髓样激酶组抑制剂的固体分散体和包含所述固体分散体的药物组合物 |
-
2020
- 2020-02-21 BR BR112021016522-3A patent/BR112021016522A2/pt not_active IP Right Cessation
- 2020-02-21 JP JP2021547541A patent/JP7577672B2/ja active Active
- 2020-02-21 PH PH1/2021/551985A patent/PH12021551985A1/en unknown
- 2020-02-21 MX MX2021010115A patent/MX2021010115A/es unknown
- 2020-02-21 PE PE2021001382A patent/PE20212153A1/es unknown
- 2020-02-21 WO PCT/KR2020/002536 patent/WO2020171646A1/ko not_active Ceased
- 2020-02-21 US US17/432,699 patent/US12433867B2/en active Active
-
2021
- 2021-08-19 CL CL2021002217A patent/CL2021002217A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220110913A1 (en) | 2022-04-14 |
| US12433867B2 (en) | 2025-10-07 |
| WO2020171646A1 (ko) | 2020-08-27 |
| JP2022521380A (ja) | 2022-04-07 |
| PH12021551985A1 (en) | 2022-08-22 |
| CL2021002217A1 (es) | 2022-04-29 |
| JP7577672B2 (ja) | 2024-11-05 |
| PE20212153A1 (es) | 2021-11-09 |
| MX2021010115A (es) | 2021-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021016522A2 (pt) | Composição farmacêutica para o tratamento da leucemia mieloide aguda | |
| US12350265B2 (en) | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | |
| KR20240167633A (ko) | 종양 치료용 약학 조성물 | |
| EP3928780A1 (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| ES3038736T3 (en) | Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma | |
| RU2657783C2 (ru) | Комбинированная терапия с использованием азабициклосоединения для ракового заболевания | |
| TWI824010B (zh) | 治療血癌之組合療法 | |
| KR20210038366A (ko) | Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 | |
| KR20200102948A (ko) | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 | |
| CN110678182A (zh) | 含有能够穿透血脑屏障的化合物作为预防或治疗脑癌的有效成分的药物组合物 | |
| KR20250100726A (ko) | 암 치료에 있어서 아제노세르팁에 대한 간헐적 투여 요법 | |
| CN118510517A (zh) | 用于治疗急性髓系白血病的flt3抑制剂和bcl-2抑制剂的治疗有效组合 | |
| TWI644667B (zh) | 脲基氮芥於癌症治療上之用途 | |
| KR20220101656A (ko) | 병용 의약 | |
| KR20250166103A (ko) | 종양 치료용 약제학적 조성물 | |
| HK40066212A (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| HK40063890A (en) | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents | |
| HK40111044A (zh) | 用於治疗急性髓系白血病的flt3抑制剂和bcl-2抑制剂的治疗有效组合 | |
| KR20220141608A (ko) | 암의 예방 또는 치료를 위한 제약 조성물 | |
| TW202015680A (zh) | 抗腫瘤劑及腫瘤治療方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2868 DE 23-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |